癌症治疗中的DNA聚合酶甲基:作用机制和调节器开发
Junwei Wu1, Yi Xu2, Linlin Xiao1
1Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou 341000, PR China.
Biochemical pharmacology
|November 4, 2025
概括
DNA聚合酶甲基 (Polθ) 是一种合成致死性点,用于同源重组缺陷的癌症. 抑制Polθ利用其在DNA修复中的作用,为BRCA突变瘤提供了一个新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
- 药物发现 药物发现 药物发现
背景情况:
- 基因聚合酶甲基 (Polθ) 对于甲基介导端结合 (TMEJ) 基因修复途径至关重要.
- 在同源重组 (HR) 缺陷癌症中,如BRCA突变瘤中的多过度表达提供了一个合成致命的目标.
- 波尔的结构包括用于DNA末端捕获的螺旋酶域和用于微同质结合和合成的聚合酶域.
研究的目的:
- 审查Polθ抑制剂在癌症治疗中的机制.
- 为了提供对Polθ的ATP结合口袋的结构洞察力.
- 讨论当前的临床试验,组合疗法以及Polθ调节器开发的最新进展.
主要方法:
- 对Polθ抑制剂的文献综述和分析.
- 对Polθ的ATP结合口袋的结构数据的检查.
- 讨论合理的药物设计,药理动力学和Polythene调节器的药理动力学.
主要成果:
- 波尔抑制剂利用HR缺乏的癌细胞对TMEJ的依赖性来生存.
- 对ATP结合口袋的结构见解指导了选择性抑制剂的设计.
- 几种Polθ抑制剂正在临床试验中,组合疗法显示出希望.
结论:
- 向抑制Polθ为HR缺乏癌症提供了可行的治疗策略.
- 对包括双重抑制剂在内的Polθ调节器的持续研究对于推进癌症治疗至关重要.
- 解决药物发现方面的挑战将为未来的Polθ向疗法铺平道路.
更多相关视频
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
3.2K
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
6.0K
相关概念视频
Translesion DNA Polymerases
11.0K
Translesion (TLS) polymerases rescue stalled DNA polymerases at sites of damaged bases by replacing the replicative polymerase and installing a nucleotide across the damaged site. Doing so, TLS allows additional time for the cell to repair the damage before resuming regular DNA replication.
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
TLS polymerases are found in all three domains of life - archaea, bacteria, and eukaryotes. Of the different classes of TLS polymerases, members of the Y family are fitted with specialized structures that...
11.0K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Proofreading
8.7K
Synthesis of new DNA molecules is carried out by the enzyme DNA polymerase, which adds nucleotides on the daughter strand complementary to the template DNA strand. DNA polymerase has a higher affinity to add the correct base and ensures fidelity during DNA replication. Furthermore, it exhibits proofreading activity during replication, using an exonuclease domain that cuts off incorrect nucleotides from the nascent DNA strand.
Errors During Replication are Corrected by the DNA Polymerase...
Errors During Replication are Corrected by the DNA Polymerase...
8.7K
Proofreading
59.7K
Overview
59.7K
Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
Eukaryotic RNA Polymerases
26.7K
RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
All three eukaryotic RNAPs require specific transcription factors, of which the...
All three eukaryotic RNAPs require specific transcription factors, of which the...
26.7K
